Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of damaged nerves after spinal trauma.
The research, published today in Clinical and Translational Medicine, used cell and animal models to demonstrate that when taken orally the candidate drug, known as AZD1390, can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, so restoring sensory and motor function after spinal injury.
The announcement comes weeks after the same research team showed a different investigational drug (AZD1236) can reduce damage after spinal cord injury, by blocking the inflammatory response. Both studies were supported by AstraZeneca’s Open Innovations Programme, which shares compounds, tools, technologies and expertise with the scientific community to advance drug discovery and development.
Read the full article here:
https://www.sciencedaily.com/releases/2022/07/220712102650.htm
Phone:
Address:
11920 Burt St., Suite 145
Omaha, NE 68154
The purpose of this site is to provide basic information, not medical or legal advice. The information is intended to be accurate, but no guarantee is made as to its accuracy, completeness, or being up to date. The owner of this web site is a lawyer. This site may be construed as advertising and promotional materials. Do not use the information on this site as an excuse to avoid seeing a lawyer. If you have a legal problem, you should seek the advice of a competent lawyer. Normally if you talk or write to an attorney, neither you nor the attorney can be forced to share the contents of what was said or written. Some courts do not follow this rule when it comes to e-mail. Also remember that most e-mail is not secure. So be careful about sending any e-mail information about your legal problems. The transmission of an e-mail request for information does not create an attorney-client relationship.